Provider of a drug discovery services intended to offer treatment for multiple sclerosis. The company's services involve uncovering novel neuroregenerative therapies, enabling healthcare providers to cure patients suffering from neurodegenerative diseases.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Out of Business | 04-Jan-2021 | Completed | Out of Business | |||
1. Early Stage VC (Series A) | Completed | Startup |